
- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Many sectors, including drug discovery, stand to benefit from advances in quantum computing. The practise of "quantum-enhanced drug discovery," which uses quantum processing to speed up the drug discovery process, has gained popularity in recent years.
The ability to correctly anticipate the behaviour of molecules in complex biological systems is one of the major challenges in drug discovery.
Utilizing traditional computing techniques can be time-consuming and expensive for this computationally demanding job. However, quantum computers have the potential to resolve these issues more quickly, enabling researchers to simulate intricate chemical interactions and more precisely anticipate the behaviour of molecules.
Numerous facets of drug discovery, including virtual screening, molecular docking, and structure-based drug design, have been addressed by quantum computing methods.
These algorithms make it possible to simulate molecular behaviour in a manner that is not possible with traditional computing techniques.
For instance, the behaviour of big molecules and macromolecular complexes can be effectively simulated by quantum computers, which can be crucial for understanding the interactions between drugs and their targets.
The optimisation of chemical reactions is another possible use for quantum computing in the search for new drugs.
The most effective methods to create a desired molecule can be found by exploring the vast universe of potential chemical reactions using quantum computers. This might shorten the process and lower the price of making novel medications.
In general, quantum-enhanced drug discovery holds the promise of greatly accelerating drug discovery and enhancing the precision of drug design.
Global Quantum-enhanced drug discovery market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
For its multidisciplinary drug discovery platform that uses quantum computer-based AI, Insilico Medicine has gotten funding. Bayer and Google Cloud are working together to scale and accelerate quantum chemistry computations in order to find new drug candidates.
The Discovery Accelerator center, the first quantum computer in the world devoted to medical research, was created by IBM and Cleveland Clinic. The centre's primary goal is to accelerate study in the fields of healthcare and life sciences using IBM's high-performance computing, hybrid cloud, and AI technologies.
According to a McKinsey report, quantum computing has the ability to significantly enhance drug discovery and development.Curavit recently received additional funding for the expansion of its virtual clinical trial capabilities, which use quantum computer-based AI for drug discovery.
According to Pharma's Almanac, quantum computing has the ability to revolutionise drug discovery and innovation.
Sl no | Topic |
1 | Market Segmentation |
2 | Scope of the report |
3 | Abbreviations |
4 | Research Methodology |
5 | Executive Summary |
6 | Introduction |
7 | Insights from Industry stakeholders |
8 | Cost breakdown of Product by sub-components and average profit margin |
9 | Disruptive innovation in the Industry |
10 | Technology trends in the Industry |
11 | Consumer trends in the industry |
12 | Recent Production Milestones |
13 | Component Manufacturing in US, EU and China |
14 | COVID-19 impact on overall market |
15 | COVID-19 impact on Production of components |
16 | COVID-19 impact on Point of sale |
17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
21 | Product installation rate by OEM, 2023 |
22 | Incline/Decline in Average B-2-B selling price in past 5 years |
23 | Competition from substitute products |
24 | Gross margin and average profitability of suppliers |
25 | New product development in past 12 months |
26 | M&A in past 12 months |
27 | Growth strategy of leading players |
28 | Market share of vendors, 2023 |
29 | Company Profiles |
30 | Unmet needs and opportunity for new suppliers |
31 | Conclusion |
32 | Appendix |